for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Grifols SA

GRLSbn.MC

Latest Trade

22.80EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

15.82

 - 

22.90

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
22.80
Open
--
Volume
--
3M AVG Volume
12.56
Today's High
--
Today's Low
--
52 Week High
22.90
52 Week Low
15.82
Shares Out (MIL)
684.14
Market Cap (MIL)
20,227.32
Forward P/E
--
Dividend (Yield %)
1.03

Next Event

Full Year 2019 Grifols SA Earnings Release

Latest Developments

More

Grifols Says Executed Non-Binding Term Sheet With Public Investment Fund Of Kingdom Of Saudi Arabia

Grifols To Launch Tavlesse In Europe

Rigel Pharmaceuticals Sees Q4 Revenue Of About $15.4 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Grifols SA

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma for therapeutic use. The Hospital division offers non-biological pharmaceutical products and medical supplies for hospital pharmacy. The Diagnostic division provides clinical analysis and laboratory testing tools to laboratories, hospitals and blood banks. The Raw materials division includes sales of intermediate biological products, as well as manufacturing services to third parties. The Company operates production facilities in Spain, the United States, Mexico and Australia, among others. It controls numerous subsidiaries, such as Kiro Grifols SL.

Contact Info

C/ Jesus y Maria, 6

+34.935.712199

http://www.grifols.com/es/web/international/home

Executive Leadership

Victor Grifols Roura

Non-Executive Chairman of the Board

Victor Grifols Deu

Co-Chief Executive Officer, Executive Director

Raimon Grifols Roura

Co-Chief Executive Officer, Executive Director

Thomas Glanzmann

Non-Executive Vice Chairman of the Board

Alfredo Arroyo Guerra

Chief Financial Officer

Key Stats

2.11 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

4.1K

2017

4.3K

2018

4.5K

2019(E)

5.0K
EPS (EUR)

2016

0.913

2017

0.860

2018

0.990

2019(E)

1.018
Price To Earnings (TTM)
41.87
Price To Sales (TTM)
4.08
Price To Book (MRQ)
4.80
Price To Cash Flow (TTM)
25.83
Total Debt To Equity (MRQ)
153.38
LT Debt To Equity (MRQ)
144.67
Return on Investment (TTM)
5.04
Return on Equity (TTM)
4.45

Latest News

Latest News

Grifols to help Saudi Arabia produce blood plasma medicines

Spanish pharmaceutical company Grifols said on Tuesday it had signed a non-binding agreement with Saudi Arabia's sovereign wealth fund to help the country produce blood plasma-derived medicines.

BRIEF-Grifols Says Executed Non-Binding Term Sheet With Public Investment Fund Of Kingdom Of Saudi Arabia

* SAYS EXECUTED NON-BINDING TERM SHEET WITH PUBLIC INVESTMENT FUND (PIF) OF KINGDOM OF SAUDI ARABIA

BRIEF-Grifols To Launch Tavlesse In Europe

* SAYS EUROPEAN COMMISSION HAS APPROVED TAVLESSE (FOSTAMATINIB) FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN ADULT PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS

Grifols says trial shows positive effects in slowing Alzheimer's

Spain's Grifols said on Friday the latest results from a clinical trial of its Alzheimer's treatment show positive effects by achieving a reduction of the disease's progression in patients with mild and moderate conditions.

Spain's Grifols, China's Shanghai RAAS form strategic alliance

Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China.

BRIEF-Grifols Says AMBAR Results Show Reduction In Progression of Moderate Alzheimer's Disease

* SAID ON SATURDAY THAT AMBAR CLINICAL TRIAL DEMONSTRATED THE ABILITY TO SLOW DOWN THE PROGRESSION OF THE DISEASE IN MODERATE ALZHEIMER'S DISEASE (AD) PATIENTS

Healthcare firm Grifols S.A. wins U.S. antitrust nod to buy Biotest US Corp

Global healthcare company, Grifols S.A. <GRLS.MC>, which is based in Spain, has won U.S. antitrust approval to buy Biotest US Corp on condition that it sells certain assets, the Federal Trade Commission said on Wednesday.

BRIEF-Grifols Q1 EBITDA Down 2.8 Pct At 297 Mln Euros YoY

* Q1 EBITDA 297.4 MILLION EUROS VERSUS 306.0 MILLION EUROS YEAR AGO

BRIEF-Grifols Concludes Experimental Phase Of Clinical Trial On Alzheimer

* SAYS CONCLUDES EXPERIMENTAL PHASE OF AMBAR, A CLINICAL TRIAL ON ALZHEIMER'S DISEASE

BRIEF-Grifols To Buy German Pharmaceutical Company Haema For 220 Mln Euros

* SAYS REACHES DEAL WITH ATON GMBH TO BUY 100 PERCENT OF HAEMA AG FOR 220 MILLION EUROS ON A DEBT FREE BASIS Source text for Eikon:

BRIEF-Grifols Announces New Agreement With Henry Schein To Distribute Normal Saline Solution In U.S.

* GRIFOLS - ANNOUNCES NEW AGREEMENT WITH HENRY SCHEIN TO DISTRIBUTE NORMAL SALINE SOLUTION IN THE U.S.

BRIEF-Grifols FY Net Profit Up At 662.7 Mln Euros

* FY NET SALES 4.32 BILLION EUROS VERSUS 4.05 BILLION EUROS YEAR AGO

BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment

* GRIFOLS HYPERRAB® (RABIES IMMUNE GLOBULIN) 300 IU/ML RECEIVES FDA APPROVAL TO TREAT PATIENTS EXPOSED TO RABIES VIRUS INFECTION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Grifols Sees Positive Impact Of 90 Mln Euros In Q4 After Revaluation Of US Assets

* SEES POSITIVE NON-RECURRING IMPACT OF ABOUT 90 MILLION EUROS NET IN Q4 FROM US TAX REFORM AND REASSESSMENT OF ASSETS RELATED TO ARADIGM Source text for Eikon:

BRIEF-Grifols Buys 51 Pct Of Medkeeper

* SAYS PURCHASE RESULT OF $98 MLN CAPITAL INCREASE IN MEDKEEPER

BRIEF-Grifols Gets Loan With EIB For 85 Mln Euros

* GETS LONG-TERM LOAN WITH THE EUROPEAN INVESTMENT BANK (EIB) FOR 85 MILLION EUROS

BRIEF-Grifols gets approval from US FDA for new product

* EARNS APPROVAL FROM US FOOD AND DRUG ADMINISTRATION (FDA) FOR NEW PRODUCT FIBRIN SEALANT (HUMAN) COMPOSED OF TWO PLASMA PROTEINS AND INDICATED FOR SURGICAL USE IN ADULTS Source text for Eikon:

BRIEF-Grifols 9-month net profit up 6.3 pct at 431.8 mln euros YoY

* 9-MONTH NET PROFIT 431.8 MILLION EUROS VERSUS 406.1 MILLION EUROS YEAR AGO

BRIEF-Grifols approves interim dividend of 0.18 eur/shr

* APPROVES INTERIM DIVIDEND OF 0.18 EURO PER SHARE PAYABLE DECEMBER 5 Source text for Eikon:

Spain's Grifols to remain in Catalonia for now - source

Spain's Grifols <GRLS.MC> has no plans to leave Catalonia at the moment but, if the current situation changes in a way which could affect the company's business, the board will take appropriate steps, a company sources said on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up